ClinicalTrials.gg
TerminatedNCT02906020MOVES-PDUpdated May 24, 2022Results posted

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

A Phase 2 interventional study of venglustat GZ/SAR402671 and Placebo in Parkinson's Disease, sponsored by Genzyme, a Sanofi Company. Terminated at 52 sites in 16 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-05-24.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment

Why this study was terminated
The topline results of the 52-week double-blind placebo-controlled period were analyzed. The study did not meet the primary or secondary endpoints. Based on these results, the decision was made to halt the long-term follow-up period of the study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
273
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,649 studies in Parkinson Disease with a site in United States — 304 open to participants now, 386 under way, 7 of them phase 3. Parkinson Disease · United States.

Enrollment
121st of 1,256
273 · median 36
Started
2016
with 72 others
Phase 2
234 of 1,649
25 open now
Registered
732nd of 1,649
by date

Among the 1,649 studies in Parkinson Disease with a site in United States, this one is the 121st largest by enrollment of the 1,256 interventional ones that give a count, is one of 73 that started in 2016, is one of 234 in phase 2, and was the 732nd registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

304 of the 1,649 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

299 more — sign in →

All 304 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,649 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

Primary Objectives:

  • Part 1: To determine the safety and tolerability of 4, 8, and 15 milligrams of GZ/SAR402671 (venglustat) administered orally for 4 weeks, as compared to placebo in participants with early-stage Parkinson's disease (PD) carrying a glucocerebrosidase gene (GBA) mutation or other pre-specified variants.
  • Part 2: To determine the efficacy of GZ/SAR402671 administered orally daily, as compared to placebo in participants with early-stage PD carrying a GBA mutation or other pre-specified variants.

Secondary Objectives:

Part 1:

  • To assess the pharmacokinetic (PK) profile of oral dosing of GZ/SAR402671 in plasma when administered in early-stage PD participants carrying a GBA mutation.
  • To assess the exposure of GZ/SAR402671 in cerebrospinal fluid (CSF) when administered in early-stage PD participants carrying a GBA mutation.

Part 2:

  • To demonstrate overall safety and tolerability of GZ/SAR402671 administered orally for 52 weeks in early-stage PD participants carrying a GBA mutation as compared to placebo.
  • To assess the pharmacodynamic response to daily oral dosing of GZ/SAR402671 in plasma and CSF as measured by glucosylceramide (GL-1) when administered in early-stage PD participants carrying a GBA mutation over a 52-week period.
Read the detailed description

Part 1: the total duration was as following:

i) Rest of the world (ROW): up to approximately 50 weeks (8.5 weeks of screening, maximum of 36 weeks of treatment and 6 weeks follow-up).

ii) Japan only: up to approximately 66 weeks (8.5 weeks of screening, maximum of 52 weeks of treatment and 6 weeks follow-up).

Part 2: the total duration was up to approximately 224 weeks that consisted of 8.5 weeks of screening period, 52 weeks of treatment period, 156 weeks of long-term follow-up (LTFU) period and 8 weeks of post-treatment period.

At the end of a 52-week main placebo-controlled treatment period, all participants were evaluated for possibility to transition to receive active treatment for 156 weeks plus 8-week post-treatment observation.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female adults with a diagnosis of PD and who were heterozygous carriers of a GBA mutation associated with PD.
  • Participants carrying known sequence variants associated with GBA-PD must had rapid eye movement (REM) sleep behavior disorder (RBD) confirmed by historically documented polysomnography or by questionnaire.
  • Age greater than or equal to (>=) 18 years to 80 years inclusive at the time of signing (FOR JAPANESE PARTICIPANTS ONLY: Age >=20 years to 80 years, inclusive, at the time of signing the informed consent. Note: Japanese participants refers only to Japanese participants enrolled and living in Japan).
  • Had symptoms of PD >=2 years.
  • Hoehn and Yahr (H and Y) stage of 2 or lower at baseline.
  • Stable medication regimen of PD drugs for at least 30 days (at least 60 days for rasagiline) prior to randomization.
  • The participant was willing to abstain from grapefruit containing products for 72 hours prior to administration of the first dose of GZ/SAR402671 and for the duration of the entire treatment period (Part 1 and Part 2, Periods 2 and 3).
  • Signed written consent.

Exclusion criteria

Exclusion criteria:

  • Parkinsonism due to drug(s) or toxin(s).
  • Participants carrying the LRRK2 G2019S mutation.
  • Participants with Gaucher disease (GD) as defined by clinical signs and symptoms (i.e., hepatosplenomegaly, cytopenia, skeletal disease) and/or marked deficiency of GCase activity compatible with GD.
  • score less than 20.
  • Participants with prior surgical history of deep brain stimulation (DBS).
  • Participants with baseline brain MRI without contrast showing a structural abnormality that is a possible cause of their PD signs or symptoms.
  • Hepatic insufficiency with liver function tests (LFT) greater than (>) 2 times at Screening Visit.
  • The participant had a documented diagnosis, as per local regulations, of any of the following infections: , , 1 or 2.
  • Renal insufficiency as defined by creatine >1.5 times normal at Screening Visit.
  • The participant had received strong or moderate inducers or inhibitors of within 30 days or 5 half-lives prior to randomization, whichever is longer.
  • The participant had, according to World Health Organization (WHO) Grading, a cortical cataract > one-quarter the lens circumference (grade cortical catact-2 [COR-2]) or a posterior subcapsular cataract >2 millimeters (grade posterior subscapsular cataract [PSC-2]). Participant with nuclear cataracts would not be excluded.
  • The participant was currently receiving potentially cataractogenic medications, including chronic regimen (more frequently than every 2 weeks) of any dose or route of or any medication that could cause cataract or worsen the vision of participants with cataract (eg, glaucoma medications) according to the Prescribing Information.
  • If female, pregnant (defined as positive beta-human chorionic gonadotrophin [Beta-HCG] blood test) or lactating or breast-feeding.
  • Any medical disorders and/or findings that, in the opinion of the Investigator, could interfere with study-related procedures. This included condition(s) that precluded the safe performance of routine lumbar punctures, such as prohibitive spinal diseases, bleeding diasthesis, or clinically significant coagulopathy or thrombocytopenia.
  • Current participation in another interventional study.
  • Any medications specifically used for treating memory dysfunction, such as, but not limited to cholinesterase inhibitors or memantine, within 30 days or 5 half-lives of these medications prior to randomization, whichever was longer.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
273 participants (actual)

Study arms

  • Experimental
    GZ/SAR402671

    Part 1: Increasing doses of GZ/SAR402671 were administered once per day. Part 2: A dose of GZ/SAR402671 (determined in Part 1) was administered once per day.

    Drug: venglustat GZ/SAR402671

  • Placebo comparator
    Placebo

    A matching placebo for Parts 1 and 2 was administered once per day.

    Drug: Placebo

Interventions

  • Drugvenglustat GZ/SAR402671

    Pharmaceutical form: capsule Route of administration: oral

  • DrugPlacebo

    Pharmaceutical form: capsule Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and does not necessarily had to have a causal relationship with the treatment. Serious AEs (SAEs) were any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were the AEs that developed or worsened or became serious during the TEAE period (defined as the period from the time of first investigational medicinal product \[IMP\] administration up of 6 weeks after the last administration of the IMP).

    Time frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)

  2. Part 1: Number of Participants With Abnormal Physical Examination Findings

    Physical examination included following observations/measurements: general appearance; heart, skin, respiratory auscultation; head, eyes, ears, nose, and throat, extremities/joints, and abdomen. New onset of abnormal physical examination was defined as a normal physical examination at Baseline and an abnormal physical examination during the treatment-emergent (TE) period (defined as the period from the time of first IMP administration up of 6 weeks after the last administration of the IMP). Abnormalities in physical examination were based on investigator's evaluation.

    Time frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)

  3. Part 1: Number of Participants With Abnormal Neurological Examination Findings

    Neurological examination included at least assessments of the participant's cranial nerves, motor system (including muscle atrophy, tone, and power), mental status, deep tendon reflex, sensation, and cerebellar function. Abnormalities in neurological examination were based on investigator's evaluation.

    Time frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)

  4. Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematology

    Criteria for potentially clinically significant abnormalities (PCSA): Hemoglobin: less than or equal to (\<=) 115 grams per liter (g/L) (Male\[M\]) or \<=95 g/L (Female\[F\]), greater than or equal to (\>=) 185 g/L (M) or \>=165 g/L (F), Decrease from baseline (DFB) \>=20 g/L; Hematocrit: \<=0.37 volume/volume (v/v) (M) or \<=0.32 v/v (F), \>=0.55 v/v (M) or \>=0.5 v/v (F); Red blood cells (RBC): \>=6 Tera/L; Platelets: less than (\<) 100 Giga/L, \>=700 Giga/L; White blood cells (WBC): \<3.0 Giga/L (Non-Black \[NB\]) or \<2.0 Giga/L (Black \[B\]), \>=16.0 Giga/L; Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); Lymphocytes: \<lower limit of normal (LLN), greater than (\>) 4.0 Giga/L; Monocytes: \<LLN, \>0.7 Giga/L; Basophils: \>0.1 Giga/L; Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L).

    Time frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)

  5. Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters

    Criteria for PCSA: Alanine Aminotransferase (ALT): \>3 ULN, \>5 ULN; Aspartate aminotransferase (AST): \>3 ULN; Alkaline phosphatase: \>1.5 ULN; Total Bilirubin: \>1.5 ULN; ALT and Bilirubin: \>3 ULN and \>2 ULN; Direct Bilirubin and Bilirubin: \>35% and \>1.5 ULN.

    Time frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)

  6. Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Parameters

    Criteria for PCSA: Creatinine: \>=150 micromoles per liter (mcmol/L) (adults), \>=30% change from baseline, \>=100% change from baseline; Blood urea nitrogen: \>=17 millimoles (mmol)/L.

    Time frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)

  7. Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic Parameters

    Criteria for PCSA: Glucose: \<=3.9 mmol/L and \<LLN; \>=11.1 mmol/L (unfasted \[unfas\]) or \>=7 mmol/L (fasted \[fas\]); Albumin: \<=25 g/L.

    Time frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)

  8. Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes Parameters

    Criteria for PCSA: Sodium: \<=129 mmol/L, \>=160 mmol/L; Potassium: \<3 mmol/L, \>=5.5 mmol/L and Chloride: \<80 mmol/L, \>115 mmol/L.

    Time frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)

  9. Part 1: Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities

    Criteria for PCSA: Systolic blood pressure (SBP) supine: \<=95 millimeters of mercury (mmHg) and DFB \>=20 mmHg; \>=160 mmHg and increase from baseline (IFB) \>=20 mmHg; Diastolic blood pressure (DBP) supine: \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg; SBP (Orthostatic): \<=-20 mmHg; DBP (Orthostatic): \<=-10 mmHg; Heart rate (HR) supine: \<=50 beats per minute (bpm) and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm; Weight: \>=5% DFB; \>=5% IFB.

    Time frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)

  10. Part 1: Number of Participants With Potentially Clinically Significant Ophthalmological Abnormalities

    Clinically significant observations in left eye, right eye and any eye (any eye among left and right) were assessed by the investigator based on methods like visual acuity, slit lamp examination, examination of the cornea, lens, and retina. Any abnormal clinically significant ophthalmological examination finding (which was present at screening or not) on any eye during the treatment-emergent period corresponded to cornea verticillata, cataract and abnormal overall evaluation

    Time frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)

  11. Part 1: Number of Participants With Potentially Clinically Significant Electrocardiogram Abnormalities

    Criteria for PCSA: HR: \<50 bpm; \<50 bpm and DFB \>=20 bpm, \<40 bpm; \>90 bpm, \<90 bpm and IFB \>=20 bpm, \>100 bpm; PR Interval: \>200 milliseconds (msec), \>200 msec and IFB \>=25%, \>220 msec; QRS Interval: \>110 msec, \>110 msec and IFB \>=25%, \>120 msec; QT Interval: \>500 msec; QTc Bazett (QTcB) interval: \>450 msec, \>480 msec, IFB \>30 and \<=60 msec, IFB \>60 msec; QTc Fridericia (QTc F): \>450 msec, \>480 msec, IFB \>30 and \<=60 msec, IFB \>60 msec.

    Time frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)

  12. Part 2: Change From Baseline to Week 52 in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II+III Total Score

    MDS-UPDRS is a multimodal scale consisting of 4 parts. Part II assessed motor experiences of daily living (total score range: 0 to 52). It contained 13 questions completed by the participant. Part III assessed the motor signs of PD and was administered by the rater (total score range: 0 to 132). Part III contained 33 scores based on 18 items. In both parts, higher score indicated more severe symptoms. For each question in both parts, numeric score was assigned between 0 to 4, where 0=Normal, 1=Slight, 2=Mild, 3=Moderate, 4=Severe. MDS-UPDRS Total Part II and III score = sum of Part II and III scores with score ranged from 0 (no symptom) to 184 (severe symptoms), where higher scores reflected more severe symptoms of PD. Data for this OM was not planned to be collected and analyzed for Part 1, Part 2: DB period re-randomized participants and Part 2 LTFU period, as pre-specified in protocol.

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Part 2: Change From Baseline to Week 52 in Parkinson's Disease Cognitive Rating Scale (PD-CRS) Total Score

    The PD-CRS detects early cognitive impairment in Parkinson's disease. It is composed of 2 scales, the fronto-subcortical scale (items: sustained attention, working memory, alternating and action verbal fluency, clock drawing, immediate, and delayed free recall verbal memory) and the posterior-cortical scale (items: confrontation naming and clock copying). The total score of the fronto-subcortical scale (sum of all items) ranged from 0 (worst) to 104 (maximum score indicates better) and the total score of the posterior-cortical scale (sum of all items) ranged from 0 (worst) to 30 (maximum score indicates better). The PD-CRS Total score = the sum of PD-CRS fronto-subcortical score and the PD-CRS posterior-cortical score, which ranged from 0 to 134, where higher score = less impairment.

    Time frame: Baseline to Week 52

  2. Part 2: Change From Baseline to Week 52 in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I+ II+III Score

    MDS-UPDRS is a multimodal scale consisting of 4 parts. Part I assessed non-motor experiences of daily living and has 2 components (total score range: 0 to 52): Part IA contained 6 questions and was assessed by the examiner (total score range: 0 to 24). Part IB contained 7 questions on non-motor experiences of daily living which was completed by the participant (total score range: 0 to 28). Part II (13 questions completed by the participant) assessed motor experiences of daily living (total score range: 0 to 52). Part III assessed motor signs of PD and was administered by the rater (total score range: 0 to 132). Part III contained 33 scores based on 18 items. In all parts, higher score indicated more symptoms. For each question, numeric score was assigned between 0 to 4, where 0=Normal, 1=Slight, 2=Mild, 3=Moderate, 4=Severe. MDS-UPDRS total score = sum of Parts I, II, and III (Range: 0 to 236). Higher score = more severe symptoms of PD.

    Time frame: Baseline to Week 52

  3. Part 2: Change From Baseline to Week 52 in Hoehn and Yahr (H and Y) Score

    H and Y scale measured how Parkinson's symptoms progress and the level of disability. Scale allocated stage scores were from 0 to 5 to indicate relative level of disability as: Stage 0: no symptoms; Stage 1: symptoms on one side of the body only; Stage 2: symptoms on both sides of the body, without impairment of balance; Stage 3: Mild to moderate bilateral disease; some postural instability; physically independent; Stage 4: Severe disability; still able to walk or stand unassisted and Stage 5: Wheelchair bound or bedridden unless aided, where higher stage score described an increased severity of disease.

    Time frame: Baseline to Week 52

07

Results

Posted Feb 28, 2022
Limitations and caveats
This study did not achieve its primary or secondary endpoints at the time of the analysis of the double-blind 52-week treatment period of Part 2 and was terminated early.

Participant flow

Study was conducted at 52 sites in 16 countries. A total of 273 participants were enrolled from 15-Dec-2016 to 18-Dec-2019. Study consisted of 2 Parts: Part 1 (dose escalation period) \& Part 2 (double-blind \[DB\] treatment period + long-term follow-up \[LTFU\]) period.

Part 1: Dose Escalation Period
Participant flow — Part 1: Dose Escalation Period
MilestonePart 1: Placebo (ROW)Part 1: Venglustat 4 mg (ROW)Part 1: Venglustat 8 mg (ROW)Part 1: Venglustat 15 mg (ROW)Part 1: Placebo (Japan Only)Part 1: Venglustat 4 mg (Japan Only)Part 1: Venglustat 8 mg (Japan Only)Part 1: Venglustat 15 mg (Japan Only)Part 2, DB Period: PlaceboPart 2, DB Period: Venglustat 15 mgPart 2, DB Period: Placebo (Re-randomized From Part 1)Part 2, DB Period: Venglustat 15 mg (Re-randomized From Part 1)Part 2, LTFU Period: Placebo Then Venglustat 15 mgPart 2, LTFU Period: Venglustat 15 mgPart 2, LTFU: Placebo Then Veng 15 mg (Re-randomized From Part 1)Part 2, LTFU: Venglustat 15 mg (Re-randomized From Part 1)
Started4454333300000000
Treated4454333300000000
Completed4353333300000000
Not completed0101000000000000
Withdrew: Adverse event0101000000000000
Part 2: Double-blind Treatment Period
Participant flow — Part 2: Double-blind Treatment Period
MilestonePart 1: Placebo (ROW)Part 1: Venglustat 4 mg (ROW)Part 1: Venglustat 8 mg (ROW)Part 1: Venglustat 15 mg (ROW)Part 1: Placebo (Japan Only)Part 1: Venglustat 4 mg (Japan Only)Part 1: Venglustat 8 mg (Japan Only)Part 1: Venglustat 15 mg (Japan Only)Part 2, DB Period: PlaceboPart 2, DB Period: Venglustat 15 mgPart 2, DB Period: Placebo (Re-randomized From Part 1)Part 2, DB Period: Venglustat 15 mg (Re-randomized From Part 1)Part 2, LTFU Period: Placebo Then Venglustat 15 mgPart 2, LTFU Period: Venglustat 15 mgPart 2, LTFU: Placebo Then Veng 15 mg (Re-randomized From Part 1)Part 2, LTFU: Venglustat 15 mg (Re-randomized From Part 1)
Started0000000011111010130000
Treated0000000011111010130000
Completed00000000998510130000
Not completed000000001225000000
Withdrew: Adverse event00000000615000000
Withdrew: Other00000000610000000
Part 2: Long-term Follow-up Period
Participant flow — Part 2: Long-term Follow-up Period
MilestonePart 1: Placebo (ROW)Part 1: Venglustat 4 mg (ROW)Part 1: Venglustat 8 mg (ROW)Part 1: Venglustat 15 mg (ROW)Part 1: Placebo (Japan Only)Part 1: Venglustat 4 mg (Japan Only)Part 1: Venglustat 8 mg (Japan Only)Part 1: Venglustat 15 mg (Japan Only)Part 2, DB Period: PlaceboPart 2, DB Period: Venglustat 15 mgPart 2, DB Period: Placebo (Re-randomized From Part 1)Part 2, DB Period: Venglustat 15 mg (Re-randomized From Part 1)Part 2, LTFU Period: Placebo Then Venglustat 15 mgPart 2, LTFU Period: Venglustat 15 mgPart 2, LTFU: Placebo Then Veng 15 mg (Re-randomized From Part 1)Part 2, LTFU: Venglustat 15 mg (Re-randomized From Part 1)
Started00000000000099851011
Treated00000000000087751011
Completed0000000000000000
Not completed00000000000099851011
Withdrew: Adverse event00000000000010400
Withdrew: Progressive disease0000000000007401
Withdrew: Lack of efficacy0000000000001100
Withdrew: Poor compliance to protocol0000000000001400
Withdrew: Study terminated by sponsor000000000000676478
Withdrew: Other00000000000013832

Outcome measures

PrimaryPart 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and does not necessarily had to have a causal relationship with the treatment. Serious AEs (SAEs) were any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were the AEs that developed or worsened or became serious during the TEAE period (defined as the period from the time of first investigational medicinal product \[IMP\] administration up of 6 weeks after the last administration of the IMP).

Time frame:
From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs)
ParticipantsPart 1: Placebo (ROW)Part 1: Venglustat 4 mg (ROW)Part 1: Venglustat 8 mg (ROW)Part 1: Venglustat 15 mg (ROW)Part 1: Placebo (Japan Only)Part 1: Venglustat 4 mg (Japan Only)Part 1: Venglustat 8 mg (Japan Only)Part 1: Venglustat 15 mg (Japan Only)
Any TEAE44442332
Any TESAE00000000
PrimaryPart 1: Number of Participants With Abnormal Physical Examination Findings

Physical examination included following observations/measurements: general appearance; heart, skin, respiratory auscultation; head, eyes, ears, nose, and throat, extremities/joints, and abdomen. New onset of abnormal physical examination was defined as a normal physical examination at Baseline and an abnormal physical examination during the treatment-emergent (TE) period (defined as the period from the time of first IMP administration up of 6 weeks after the last administration of the IMP). Abnormalities in physical examination were based on investigator's evaluation.

Time frame:
From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Abnormal Physical Examination Findings
ParticipantsPart 1: Placebo (ROW)Part 1: Venglustat 4 mg (ROW)Part 1: Venglustat 8 mg (ROW)Part 1: Venglustat 15 mg (ROW)Part 1: Placebo (Japan Only)Part 1: Venglustat 4 mg (Japan Only)Part 1: Venglustat 8 mg (Japan Only)Part 1: Venglustat 15 mg (Japan Only)
Part 1: Number of Participants With Abnormal Physical Examination Findings00120000
PrimaryPart 1: Number of Participants With Abnormal Neurological Examination Findings

Neurological examination included at least assessments of the participant's cranial nerves, motor system (including muscle atrophy, tone, and power), mental status, deep tendon reflex, sensation, and cerebellar function. Abnormalities in neurological examination were based on investigator's evaluation.

Time frame:
From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Abnormal Neurological Examination Findings
ParticipantsPart 1: Placebo (ROW)Part 1: Venglustat 4 mg (ROW)Part 1: Venglustat 8 mg (ROW)Part 1: Venglustat 15 mg (ROW)Part 1: Placebo (Japan Only)Part 1: Venglustat 4 mg (Japan Only)Part 1: Venglustat 8 mg (Japan Only)Part 1: Venglustat 15 mg (Japan Only)
Abnormal cranial nerve examination11121332
Abnormal motor examination34433333
Abnormal strength examination14331221
Abnormal reflex examination01110220
Abnormal sensory examination02010100
Abnormal coordination examination21131012
Abnormal gait and coordination34423222
PrimaryPart 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematology

Criteria for potentially clinically significant abnormalities (PCSA): Hemoglobin: less than or equal to (\<=) 115 grams per liter (g/L) (Male\[M\]) or \<=95 g/L (Female\[F\]), greater than or equal to (\>=) 185 g/L (M) or \>=165 g/L (F), Decrease from baseline (DFB) \>=20 g/L; Hematocrit: \<=0.37 volume/volume (v/v) (M) or \<=0.32 v/v (F), \>=0.55 v/v (M) or \>=0.5 v/v (F); Red blood cells (RBC): \>=6 Tera/L; Platelets: less than (\<) 100 Giga/L, \>=700 Giga/L; White blood cells (WBC): \<3.0 Giga/L (Non-Black \[NB\]) or \<2.0 Giga/L (Black \[B\]), \>=16.0 Giga/L; Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); Lymphocytes: \<lower limit of normal (LLN), greater than (\>) 4.0 Giga/L; Monocytes: \<LLN, \>0.7 Giga/L; Basophils: \>0.1 Giga/L; Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L).

Time frame:
From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematology
ParticipantsPart 1: Placebo (ROW)Part 1: Venglustat 4 mg (ROW)Part 1: Venglustat 8 mg (ROW)Part 1: Venglustat 15 mg (ROW)Part 1: Placebo (Japan Only)Part 1: Venglustat 4 mg (Japan Only)Part 1: Venglustat 8 mg (Japan Only)Part 1: Venglustat 15 mg (Japan Only)
Hemoglobin <= 115 g/L (M); ≤ 95 g/L (F)00000000
Hemoglobin >=185 g/L (M) or >=165 g/L (F)00000000
Hemoglobin DFB >=20 g/L10110001
Hematocrit: <=0.37 v/v (M) or <=0.32 v/v (F)00120000
Hematocrit: >=0.55 v/v (M); >=0.5 v/v (F)00000000
RBC: >=6 Tera/L00000000
Platelets: <100 Giga/L00100000
Platelets: >=700 Giga/L00000000
WBC: <3.0 Giga/L (NB) or <2.0 Giga/L (B)00000000
WBC: >=16.0 Giga/L00000000
Neutrophils <1.5 Giga/L (NB) or <1.0 Giga/L (B)00000000
Lymphocytes: <LLN01000010
Lymphocytes: >4.0 Giga/L00000000
Monocytes: <LLN00000000
Monocytes: >0.7 Giga/L00200000
Basophils: >0.1 Giga/L00000000
Eosinophils >0.5 Giga/L or >ULN (ULN >=0.5 Giga/L)00000000
PrimaryPart 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters

Criteria for PCSA: Alanine Aminotransferase (ALT): \>3 ULN, \>5 ULN; Aspartate aminotransferase (AST): \>3 ULN; Alkaline phosphatase: \>1.5 ULN; Total Bilirubin: \>1.5 ULN; ALT and Bilirubin: \>3 ULN and \>2 ULN; Direct Bilirubin and Bilirubin: \>35% and \>1.5 ULN.

Time frame:
From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters
ParticipantsPart 1: Placebo (ROW)Part 1: Venglustat 4 mg (ROW)Part 1: Venglustat 8 mg (ROW)Part 1: Venglustat 15 mg (ROW)Part 1: Placebo (Japan Only)Part 1: Venglustat 4 mg (Japan Only)Part 1: Venglustat 8 mg (Japan Only)Part 1: Venglustat 15 mg (Japan Only)
ALT >3 ULN00001010
ALT >5 ULN00000000
AST >3 ULN00001000
AST >5 ULN00000000
Alkaline Phosphatase >1.5 ULN00001000
Total Bilirubin > 1.5 ULN00000000
ALT and Bilirubin: >3 ULN and >2 ULN00000000
Direct Bilirubin and Bilirubin: >35% and >1.5 ULN00000000
PrimaryPart 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Parameters

Criteria for PCSA: Creatinine: \>=150 micromoles per liter (mcmol/L) (adults), \>=30% change from baseline, \>=100% change from baseline; Blood urea nitrogen: \>=17 millimoles (mmol)/L.

Time frame:
From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Parameters
ParticipantsPart 1: Placebo (ROW)Part 1: Venglustat 4 mg (ROW)Part 1: Venglustat 8 mg (ROW)Part 1: Venglustat 15 mg (ROW)Part 1: Placebo (Japan Only)Part 1: Venglustat 4 mg (Japan Only)Part 1: Venglustat 8 mg (Japan Only)Part 1: Venglustat 15 mg (Japan Only)
Creatinine >=150 mcmol/L (Adults)00000000
Creatinine >=30% change from baseline00000010
Creatinine >=100% change from baseline00000000
Blood Urea Nitrogen >=17 mmol/L00000000
PrimaryPart 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic Parameters

Criteria for PCSA: Glucose: \<=3.9 mmol/L and \<LLN; \>=11.1 mmol/L (unfasted \[unfas\]) or \>=7 mmol/L (fasted \[fas\]); Albumin: \<=25 g/L.

Time frame:
From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic Parameters
ParticipantsPart 1: Placebo (ROW)Part 1: Venglustat 4 mg (ROW)Part 1: Venglustat 8 mg (ROW)Part 1: Venglustat 15 mg (ROW)Part 1: Placebo (Japan Only)Part 1: Venglustat 4 mg (Japan Only)Part 1: Venglustat 8 mg (Japan Only)Part 1: Venglustat 15 mg (Japan Only)
Glucose <=3.9 mmol/L and <LLN00000000
Glucose >=11.1 mmol/L (unfas) or >=7 mmol/L (fas)00000100
Albumin <=25 g/L00000000
PrimaryPart 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes Parameters

Criteria for PCSA: Sodium: \<=129 mmol/L, \>=160 mmol/L; Potassium: \<3 mmol/L, \>=5.5 mmol/L and Chloride: \<80 mmol/L, \>115 mmol/L.

Time frame:
From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes Parameters
ParticipantsPart 1: Placebo (ROW)Part 1: Venglustat 4 mg (ROW)Part 1: Venglustat 8 mg (ROW)Part 1: Venglustat 15 mg (ROW)Part 1: Placebo (Japan Only)Part 1: Venglustat 4 mg (Japan Only)Part 1: Venglustat 8 mg (Japan Only)Part 1: Venglustat 15 mg (Japan Only)
Sodium <=129 mmol/L00000000
Sodium >=160 mmol/L00000000
Potassium <3 mmol/L00000000
Potassium >=5.5 mmol/L00000000
Chloride <80 mmol/L00000000
Chloride >115 mmol/L00000000
PrimaryPart 1: Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities

Criteria for PCSA: Systolic blood pressure (SBP) supine: \<=95 millimeters of mercury (mmHg) and DFB \>=20 mmHg; \>=160 mmHg and increase from baseline (IFB) \>=20 mmHg; Diastolic blood pressure (DBP) supine: \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg; SBP (Orthostatic): \<=-20 mmHg; DBP (Orthostatic): \<=-10 mmHg; Heart rate (HR) supine: \<=50 beats per minute (bpm) and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm; Weight: \>=5% DFB; \>=5% IFB.

Time frame:
From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities
ParticipantsPart 1: Placebo (ROW)Part 1: Venglustat 4 mg (ROW)Part 1: Venglustat 8 mg (ROW)Part 1: Venglustat 15 mg (ROW)Part 1: Placebo (Japan Only)Part 1: Venglustat 4 mg (Japan Only)Part 1: Venglustat 8 mg (Japan Only)Part 1: Venglustat 15 mg (Japan Only)
SBP (supine) <=95 mmHg and DFB >=20 mmHg00100020
SBP (supine) >=160 mmHg and IFB >=20 mmHg00020000
DBP (supine) <=45 mmHg and DFB >=10 mmHg00000000
DBP (supine) >=110 mmHg and IFB >=10 mmHg00000000
SBP (Orthostatic): <=-20 mmHg00000000
DBP (Orthostatic): <=-10 mmHg00000000
HR (supine) <=50 bpm and DFB >= 20 bpm00000000
HR (supine) >=120 bpm and IFB >=20 bpm00000000
Weight >=5% DFB00100000
Weight >=5% IFB10100000
PrimaryPart 1: Number of Participants With Potentially Clinically Significant Ophthalmological Abnormalities

Clinically significant observations in left eye, right eye and any eye (any eye among left and right) were assessed by the investigator based on methods like visual acuity, slit lamp examination, examination of the cornea, lens, and retina. Any abnormal clinically significant ophthalmological examination finding (which was present at screening or not) on any eye during the treatment-emergent period corresponded to cornea verticillata, cataract and abnormal overall evaluation

Time frame:
From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Potentially Clinically Significant Ophthalmological Abnormalities
ParticipantsPart 1: Placebo (ROW)Part 1: Venglustat 4 mg (ROW)Part 1: Venglustat 8 mg (ROW)Part 1: Venglustat 15 mg (ROW)Part 1: Placebo (Japan Only)Part 1: Venglustat 4 mg (Japan Only)Part 1: Venglustat 8 mg (Japan Only)Part 1: Venglustat 15 mg (Japan Only)
Any eye33422330
Right eye33422230
Left eye33422330
PrimaryPart 1: Number of Participants With Potentially Clinically Significant Electrocardiogram Abnormalities

Criteria for PCSA: HR: \<50 bpm; \<50 bpm and DFB \>=20 bpm, \<40 bpm; \>90 bpm, \<90 bpm and IFB \>=20 bpm, \>100 bpm; PR Interval: \>200 milliseconds (msec), \>200 msec and IFB \>=25%, \>220 msec; QRS Interval: \>110 msec, \>110 msec and IFB \>=25%, \>120 msec; QT Interval: \>500 msec; QTc Bazett (QTcB) interval: \>450 msec, \>480 msec, IFB \>30 and \<=60 msec, IFB \>60 msec; QTc Fridericia (QTc F): \>450 msec, \>480 msec, IFB \>30 and \<=60 msec, IFB \>60 msec.

Time frame:
From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Potentially Clinically Significant Electrocardiogram Abnormalities
ParticipantsPart 1: Placebo (ROW)Part 1: Venglustat 4 mg (ROW)Part 1: Venglustat 8 mg (ROW)Part 1: Venglustat 15 mg (ROW)Part 1: Placebo (Japan Only)Part 1: Venglustat 4 mg (Japan Only)Part 1: Venglustat 8 mg (Japan Only)Part 1: Venglustat 15 mg (Japan Only)
HR: <50 bpm01101000
HR: <50 bpm and DFB >=20 bpm00000000
HR: <40 bpm00000000
HR: >90 bpm00000011
HR: >90 bpm and IFB >=20 bpm00000000
HR: >100 bpm00000000
PR Interval: >200 msec00000200
PR Interval: >200 msec and IFB >=25%00000000
PR Interval: >220 msec00000000
QRS Interval: >110 msec01110000
QRS Interval: >110 msec and IFB >=25%00000000
QRS Interval: >120 msec00100000
QT Interval: >500 msec00000000
QTcB interval: >450 msec00100000
QTcB interval: >480 msec00000000
QTcB interval: IFB >30 and <=60 msec00100001
QTcB interval: IFB >60 msec00000000
QTc F: >450 msec00100000
QTc F: >480 msec00000000
QTc F: IFB >30 and <=60 msec00100001
QTc F: IFB >60 msec00000000
PrimaryPart 2: Change From Baseline to Week 52 in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II+III Total Score

MDS-UPDRS is a multimodal scale consisting of 4 parts. Part II assessed motor experiences of daily living (total score range: 0 to 52). It contained 13 questions completed by the participant. Part III assessed the motor signs of PD and was administered by the rater (total score range: 0 to 132). Part III contained 33 scores based on 18 items. In both parts, higher score indicated more severe symptoms. For each question in both parts, numeric score was assigned between 0 to 4, where 0=Normal, 1=Slight, 2=Mild, 3=Moderate, 4=Severe. MDS-UPDRS Total Part II and III score = sum of Part II and III scores with score ranged from 0 (no symptom) to 184 (severe symptoms), where higher scores reflected more severe symptoms of PD. Data for this OM was not planned to be collected and analyzed for Part 1, Part 2: DB period re-randomized participants and Part 2 LTFU period, as pre-specified in protocol.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · units on a scale
Part 2: Change From Baseline to Week 52 in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II+III Total Score
units on a scalePart 2, DB Period: PlaceboPart 2, DB Period: Venglustat 15 mg
Part 2: Change From Baseline to Week 52 in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II+III Total Score4.71 ± 1.277.29 ± 1.36
Statistical analysis
  • Part 2, DB Period: Placebo vs Part 2, DB Period: Venglustat 15 mg · MMRM · p = =0.1679 (The threshold for statistical significance was 0.05.) · Ls mean difference: 2.58 · 95% CI -1.10 to 6.27
SecondaryPart 2: Change From Baseline to Week 52 in Parkinson's Disease Cognitive Rating Scale (PD-CRS) Total Score

The PD-CRS detects early cognitive impairment in Parkinson's disease. It is composed of 2 scales, the fronto-subcortical scale (items: sustained attention, working memory, alternating and action verbal fluency, clock drawing, immediate, and delayed free recall verbal memory) and the posterior-cortical scale (items: confrontation naming and clock copying). The total score of the fronto-subcortical scale (sum of all items) ranged from 0 (worst) to 104 (maximum score indicates better) and the total score of the posterior-cortical scale (sum of all items) ranged from 0 (worst) to 30 (maximum score indicates better). The PD-CRS Total score = the sum of PD-CRS fronto-subcortical score and the PD-CRS posterior-cortical score, which ranged from 0 to 134, where higher score = less impairment.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · units on a scale
Part 2: Change From Baseline to Week 52 in Parkinson's Disease Cognitive Rating Scale (PD-CRS) Total Score
units on a scalePart 2, DB Period: PlaceboPart 2, DB Period: Venglustat 15 mg
Part 2: Change From Baseline to Week 52 in Parkinson's Disease Cognitive Rating Scale (PD-CRS) Total Score0.32 ± 1.27-0.65 ± 1.35
Statistical analysis
  • Part 2, DB Period: Placebo vs Part 2, DB Period: Venglustat 15 mg · MMRM · p = =0.5996 (The threshold for statistical significance was 0.05.) · Ls mean difference: -0.97 · 95% CI -4.63 to 2.68
SecondaryPart 2: Change From Baseline to Week 52 in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I+ II+III Score

MDS-UPDRS is a multimodal scale consisting of 4 parts. Part I assessed non-motor experiences of daily living and has 2 components (total score range: 0 to 52): Part IA contained 6 questions and was assessed by the examiner (total score range: 0 to 24). Part IB contained 7 questions on non-motor experiences of daily living which was completed by the participant (total score range: 0 to 28). Part II (13 questions completed by the participant) assessed motor experiences of daily living (total score range: 0 to 52). Part III assessed motor signs of PD and was administered by the rater (total score range: 0 to 132). Part III contained 33 scores based on 18 items. In all parts, higher score indicated more symptoms. For each question, numeric score was assigned between 0 to 4, where 0=Normal, 1=Slight, 2=Mild, 3=Moderate, 4=Severe. MDS-UPDRS total score = sum of Parts I, II, and III (Range: 0 to 236). Higher score = more severe symptoms of PD.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · units on a scale
Part 2: Change From Baseline to Week 52 in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I+ II+III Score
units on a scalePart 2, DB Period: PlaceboPart 2, DB Period: Venglustat 15 mg
Part 2: Change From Baseline to Week 52 in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I+ II+III Score5.87 ± 1.459.99 ± 1.55
Statistical analysis
  • Part 2, DB Period: Placebo vs Part 2, DB Period: Venglustat 15 mg · MMRM · p = =0.0535 (The threshold for statistical significance was 0.05.) · Ls mean difference: 4.13 · 95% CI -0.06 to 8.32
SecondaryPart 2: Change From Baseline to Week 52 in Hoehn and Yahr (H and Y) Score

H and Y scale measured how Parkinson's symptoms progress and the level of disability. Scale allocated stage scores were from 0 to 5 to indicate relative level of disability as: Stage 0: no symptoms; Stage 1: symptoms on one side of the body only; Stage 2: symptoms on both sides of the body, without impairment of balance; Stage 3: Mild to moderate bilateral disease; some postural instability; physically independent; Stage 4: Severe disability; still able to walk or stand unassisted and Stage 5: Wheelchair bound or bedridden unless aided, where higher stage score described an increased severity of disease.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · units on a scale
Part 2: Change From Baseline to Week 52 in Hoehn and Yahr (H and Y) Score
units on a scalePart 2, DB Period: PlaceboPart 2, DB Period: Venglustat 15 mg
Part 2: Change From Baseline to Week 52 in Hoehn and Yahr (H and Y) Score0.18 ± 0.050.20 ± 0.06
Statistical analysis
  • Part 2, DB Period: Placebo vs Part 2, DB Period: Venglustat 15 mg · MMRM · p = =0.7400 (The threshold for statistical significance was 0.05.) · Ls mean difference: 0.03 · 95% CI -0.12 to 0.17

Adverse events

Collected over From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., in Part 1: up to 42 weeks for ROW, up to 58 weeks for Japanese participants; in Part 2 DB period: up to 60 weeks; in Part 2 LTFU period: up to 164 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Placebo (ROW)0/4 (0%)0/4 (0%)4/4 (100%)
Part 1: Venglustat 4 mg (ROW)0/4 (0%)0/4 (0%)4/4 (100%)
Part 1: Venglustat 8 mg (ROW)0/5 (0%)0/5 (0%)4/5 (80%)
Part 1: Venglustat 15 mg (ROW)0/4 (0%)0/4 (0%)4/4 (100%)
Part 1: Placebo (Japan Only)0/3 (0%)0/3 (0%)2/3 (66.7%)
Part 1: Venglustat 4 mg (Japan Only)0/3 (0%)0/3 (0%)3/3 (100%)
Part 1: Venglustat 8 mg (Japan Only)0/3 (0%)0/3 (0%)3/3 (100%)
Part 1: Venglustat 15 mg (Japan Only)0/3 (0%)0/3 (0%)2/3 (66.7%)
Part 2, DB Period: Placebo0/111 (0%)12/111 (10.8%)87/111 (78.4%)
Part 2, DB Period: Venglustat 15 mg1/110 (0.9%)12/110 (10.9%)95/110 (86.4%)
Part 2, DB Period: Placebo (Re-randomized From Part 1)0/10 (0%)0/10 (0%)8/10 (80%)
Part 2, DB Period: Venglustat 15 mg (Re-randomized From Part 1)0/13 (0%)3/13 (23.1%)11/13 (84.6%)
Part 2, LTFU Period: Placebo Then Venglustat 15 mg1/87 (1.1%)15/87 (17.2%)53/87 (60.9%)
Part 2, LTFU Period: Venglustat 15 mg0/75 (0%)9/75 (12%)39/75 (52%)
Part 2, LTFU: Placebo Then Veng 15 mg (Re-randomized From Part 1)0/10 (0%)3/10 (30%)7/10 (70%)
Part 2, LTFU: Venglustat 15 mg (Re-randomized From Part 1)0/11 (0%)1/11 (9.1%)8/11 (72.7%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
EventPart 1: Placebo (ROW)Part 1: Venglustat 4 mg (ROW)Part 1: Venglustat 8 mg (ROW)Part 1: Venglustat 15 mg (ROW)Part 1: Placebo (Japan Only)Part 1: Venglustat 4 mg (Japan Only)Part 1: Venglustat 8 mg (Japan Only)Part 1: Venglustat 15 mg (Japan Only)Part 2, DB Period: PlaceboPart 2, DB Period: Venglustat 15 mgPart 2, DB Period: Placebo (Re-randomized From Part 1)Part 2, DB Period: Venglustat 15 mg (Re-randomized From Part 1)Part 2, LTFU Period: Placebo Then Venglustat 15 mgPart 2, LTFU Period: Venglustat 15 mgPart 2, LTFU: Placebo Then Veng 15 mg (Re-randomized From Part 1)Part 2, LTFU: Venglustat 15 mg (Re-randomized From Part 1)
Covid-19Infections and infestations0/40/40/50/40/30/30/30/30/1110/1100/100/130/870/751/100/11
Cognitive DisorderNervous system disorders0/40/40/50/40/30/30/30/30/1111/1100/100/130/870/751/100/11
Confusional StatePsychiatric disorders0/40/40/50/40/30/30/30/30/1110/1100/100/130/871/751/100/11
Intentional OverdoseInjury, poisoning and procedural complications0/40/40/50/40/30/30/30/30/1110/1100/100/130/870/750/101/11
Suicide AttemptPsychiatric disorders0/40/40/50/40/30/30/30/30/1110/1100/100/130/870/750/101/11
Inguinal HerniaGastrointestinal disorders0/40/40/50/40/30/30/30/30/1110/1100/101/130/870/750/100/11
PneumoniaInfections and infestations0/40/40/50/40/30/30/30/30/1110/1100/101/130/870/750/100/11
SepsisInfections and infestations0/40/40/50/40/30/30/30/30/1110/1100/101/130/870/750/100/11
Urinary Tract InfectionInfections and infestations0/40/40/50/40/30/30/30/30/1110/1100/101/131/870/750/100/11
Transient Ischaemic AttackNervous system disorders0/40/40/50/40/30/30/30/30/1111/1100/101/130/870/750/100/11
Most frequent other events
Showing 10 of 120
Most frequent other events
EventPart 1: Placebo (ROW)Part 1: Venglustat 4 mg (ROW)Part 1: Venglustat 8 mg (ROW)Part 1: Venglustat 15 mg (ROW)Part 1: Placebo (Japan Only)Part 1: Venglustat 4 mg (Japan Only)Part 1: Venglustat 8 mg (Japan Only)Part 1: Venglustat 15 mg (Japan Only)Part 2, DB Period: PlaceboPart 2, DB Period: Venglustat 15 mgPart 2, DB Period: Placebo (Re-randomized From Part 1)Part 2, DB Period: Venglustat 15 mg (Re-randomized From Part 1)Part 2, LTFU Period: Placebo Then Venglustat 15 mgPart 2, LTFU Period: Venglustat 15 mgPart 2, LTFU: Placebo Then Veng 15 mg (Re-randomized From Part 1)Part 2, LTFU: Venglustat 15 mg (Re-randomized From Part 1)
NauseaGastrointestinal disorders1/41/40/50/40/32/30/30/38/11123/1100/101/135/870/750/101/11
VomitingGastrointestinal disorders0/40/40/50/40/32/30/30/33/1119/1100/100/134/870/750/100/11
ArthralgiaMusculoskeletal and connective tissue disorders0/42/40/50/40/30/30/30/37/1115/1101/101/130/874/750/100/11
HeadacheNervous system disorders2/40/41/50/40/31/30/30/315/11122/1100/103/132/873/750/100/11
AnxietyPsychiatric disorders0/40/40/52/40/30/30/30/36/1115/1100/102/137/872/751/100/11
DiarrhoeaGastrointestinal disorders0/40/42/50/40/30/30/30/34/1115/1100/100/131/871/750/100/11
Hallucination, VisualPsychiatric disorders0/40/42/50/40/30/30/30/30/1111/1100/101/131/871/751/100/11
VertigoEar and labyrinth disorders0/40/40/51/40/31/30/30/32/1110/1101/100/131/870/750/100/11
GlaucomaEye disorders0/40/40/50/40/30/31/30/30/1111/1100/100/130/871/750/100/11
Abdominal DiscomfortGastrointestinal disorders0/40/40/50/40/31/30/30/30/1110/1100/100/130/870/750/100/11

Baseline characteristics

Analysis was performed on all randomized unique participants (N=250) only.

Age, Continuous
Age, Continuous(years)Part 1: Placebo (ROW)Part 1: Venglustat 4 mg (ROW)Part 1: Venglustat 8 mg (ROW)Part 1: Venglustat 15 mg (ROW)Part 1: Placebo (Japan Only)Part 1: Venglustat 4 mg (Japan Only)Part 1: Venglustat 8 mg (Japan Only)Part 1: Venglustat 15 mg (Japan Only)Part 2, DB Period: PlaceboPart 2, DB Period: Venglustat 15 mgTotal Title
Mean53.0 ± 8.855.0 ± 3.961.0 ± 6.963.8 ± 8.752.0 ± 10.461.7 ± 5.956.7 ± 4.046.7 ± 8.159.8 ± 8.558.2 ± 9.858.7 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Placebo (ROW)Part 1: Venglustat 4 mg (ROW)Part 1: Venglustat 8 mg (ROW)Part 1: Venglustat 15 mg (ROW)Part 1: Placebo (Japan Only)Part 1: Venglustat 4 mg (Japan Only)Part 1: Venglustat 8 mg (Japan Only)Part 1: Venglustat 15 mg (Japan Only)Part 2, DB Period: PlaceboPart 2, DB Period: Venglustat 15 mgTotal Title
Female11110311434597
Male334330226865153
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Placebo (ROW)Part 1: Venglustat 4 mg (ROW)Part 1: Venglustat 8 mg (ROW)Part 1: Venglustat 15 mg (ROW)Part 1: Placebo (Japan Only)Part 1: Venglustat 4 mg (Japan Only)Part 1: Venglustat 8 mg (Japan Only)Part 1: Venglustat 15 mg (Japan Only)Part 2, DB Period: PlaceboPart 2, DB Period: Venglustat 15 mgTotal Title
American Indian or Alaska Native00000000000
Asian0000333371029
Native Hawaiian or Other Pacific Islander00000000000
Black or African American00000000000
White44540000104100221
More than one race00000000000
Unknown or Not Reported00000000000
08

Study locations

52 sites
  • Investigational Site Number :8400017
    Scottsdale, Arizona 85258, United States
  • Investigational Site Number :8400011
    Scottsdale, Arizona 85259, United States
  • Investigational Site Number :8400004
    La Jolla, California 92093, United States
  • Investigational Site Number :8400019
    Palo Alto, California 94304, United States
  • Investigational Site Number :8400013
    Sunnyvale, California 94085, United States
  • Investigational Site Number :8400015
    New Haven, Connecticut 06510, United States
  • Investigational Site Number :8400008
    Boca Raton, Florida 33486, United States
  • Investigational Site Number :8400016
    Chicago, Illinois 60611, United States
  • Investigational Site Number :8400005
    Chicago, Illinois 60612-3854, United States
  • Investigational Site Number :8400014
    Boston, Massachusetts 02114, United States
  • Investigational Site Number :8400018
    New York, New York 10003, United States
  • Investigational Site Number :8400010
    New York, New York 10016, United States
  • Investigational Site Number :8400001
    New York, New York 10032, United States
  • Investigational Site Number :8400021
    Portland, Oregon 97210, United States
  • Investigational Site Number :8400020
    Portland, Oregon 97225, United States
  • Investigational Site Number :8400009
    Portland, Oregon 97239, United States
  • Investigational Site Number :8400002
    Philadelphia, Pennsylvania 19107, United States
  • Investigational Site Number :8400006
    Fairfax, Virginia 22030, United States
  • Investigational Site Number :8400012
    Kirkland, Washington 98034, United States
  • Investigational Site Number :0400001
    Innsbruck, 6020, Austria
  • Investigational Site Number :1240003
    Vancouver, British Columbia V6T 2B5, Canada
  • Investigational Site Number :1240002
    Ottawa, Ontario K1Y 4E9, Canada
  • Investigational Site Number :1240001
    Montreal, Quebec H3A 2B4, Canada
  • Investigational Site Number :2500001
    Paris, 75013, France
  • Investigational Site Number :2760002
    Kiel, 24105, Germany
  • Investigational Site Number :2760001
    Tübingen, 72076, Germany
  • Investigational Site Number :3000002
    Larissa, 41110, Greece
  • Investigational Site Number :3760002
    Haifa, 3109601, Israel
  • Investigational Site Number :3760003
    Petah-Tikva, 49100, Israel
  • Investigational Site Number :3760001
    Tel Aviv, 64239, Israel
  • Investigational Site Number :3760004
    Tel HaShomer, 52621, Israel
  • Investigational Site Number :3800006
    Rozzano, Milano 20089, Italy
  • Investigational Site Number :3800001
    Catanzaro, 88100, Italy
  • Investigational Site Number :3800004
    Milano, 20126, Italy
  • Investigational Site Number :3800003
    Pavia, 27100, Italy
  • Investigational Site Number :3800002
    Salerno, 84131, Italy
  • Investigational Site Number :3920005
    Nagoya-shi, Aichi 466-8560, Japan
  • Investigational Site Number :3920002
    Kyoto-shi, Kyoto 606-8507, Japan
  • Investigational Site Number :3920004
    Osaka-shi, Osaka 530-8480, Japan
  • Investigational Site Number :3920001
    Bunkyo-ku, Tokyo 113-8431, Japan
  • Investigational Site Number :3920003
    Kodaira-shi, Tokyo 187-8551, Japan
  • Investigational Site Number :5780001
    Trondheim, 7006, Norway
  • Investigational Site Number :6200002
    Coimbra, 3000-075, Portugal
  • Investigational Site Number :6200003
    Torres Vedras, 2560-280, Portugal
  • Investigational Site Number :7020001
    Singapore, 169608, Singapore
  • Investigational Site Number :7020002
    Singapore, 308433, Singapore
  • Investigational Site Number :7240002
    Barcelona, Barcelona [Barcelona] 08025, Spain
  • Investigational Site Number :7240001
    Sevilla, 41013, Spain
  • Investigational Site Number :7520001
    Stockholm, 14186, Sweden
  • Investigational Site Number :1580001
    Taoyuan County, 33305, Taiwan
  • Investigational Site Number :8260001
    London, London, City Of NW1 2PG, United Kingdom
  • Investigational Site Number :8260002
    Oxford, Oxfordshire OX3 9DZ, United Kingdom
09

References and documents

Publications

  • Peterschmitt MJ, Saiki H, Hatano T, Gasser T, Isaacson SH, Gaemers SJM, Minini P, Saubadu S, Sharma J, Walbillic S, Alcalay RN, Cutter G, Hattori N, Hoglinger GU, Marek K, Schapira AHV, Scherzer CR, Simuni T, Giladi N, Sardi SP, Fischer TZ; MOVES-PD Investigators. Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. J Parkinsons Dis. 2022;12(2):557-570. doi: 10.3233/JPD-212714. PubMed 34897099 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Dec 2020, 48 months.

Results were first posted in Feb 2022, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2016
First posted
Sep 19, 2016
StartActual
Dec 15, 2016
Primary completionActual
Dec 18, 2020
CompletionActual
May 27, 2021
Results first posted
Feb 28, 2022
Last update
May 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02906020
Responsible party
Sponsor
First posted
Sep 19, 2016
Start date
Dec 15, 2016
Primary completion
Dec 18, 2020
Completion
May 27, 2021
Results posted
Feb 28, 2022
Last update
May 24, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion